Identification, Characterization and Application of a G-Quadruplex Structured DNA Aptamer against Cancer Biomarker Protein Anterior Gradient Homolog 2 by Jie Wu et al.
Identification, Characterization and Application of a G-
Quadruplex Structured DNA Aptamer against Cancer
Biomarker Protein Anterior Gradient Homolog 2
Jie Wu1., Chi Wang1., Xilan Li1, Yanling Song1, Wei Wang1, Cong Li1, Jia Hu1, Zhi Zhu1*, Jiuxing Li1,
Weiyun Zhang1, Zhongxian Lu2*, Chaoyong James Yang1*
1 State Key Laboratory of Physical Chemistry of Solid Surface, Key Laboratory for Chemical Biology of Fujian Province, Key Laboratory of Analytical Sciences, and
Department of Chemical Biology, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, People’s Republic of China, 2 Xiamen City Key Laboratory of
Metabolism Disease, School of Pharmaceutical Sciences, Xiamen University, Xiamen, China
Abstract
Background: Anterior gradient homolog 2 (AGR2) is a functional protein with critical roles in a diverse range of biological
systems, including vertebrate tissue development, inflammatory tissue injury responses, and cancer progression. Clinical
studies have shown that the AGR2 protein is overexpressed in a wide range of human cancers, including carcinomas of the
esophagus, pancreas, breast, prostate, and lung, making the protein as a potential cancer biomarker. However, the general
biochemical functions of AGR2 in human cells remain undefined, and the signaling mechanisms that drive AGR2 to inhibit
p53 are still not clearly illustrated. Therefore, it is of great interest to develop molecular probes specifically recognizing AGR2
for its detection and for the elucidation of AGR2-associated molecular mechanism.
Methodology/Principal Findings: Through a bead-based and flow cytometry monitored SELEX technology, we have
identified a group of DNA aptamers that can specifically bind to AGR2 with Kd values in the nanomolar range after 14
rounds of selections. Aptamer C14B was chosen to further study, due to its high binding affinity and specificity. The
optimized and shortened C14B1 has special G-rich characteristics, and the G-rich region of this binding motif was further
characterized to reveal an intramolecular parallel G-quadruplex by CD spectroscopy and UV spectroscopy. Our experiments
confirmed that the stability of the G-quadruplex structure was strongly dependent on the nature of the monovalent ions
and the formation of G-quadruplex structure was also important for the binding capacity of C14B1 to the target.
Furthermore, we have designed a kind of allosteric molecule beacon (aMB) probe for selective and sensitive detection of
AGR2.
Conclusion/Significance: In this work, we have developed new aptamer probes for specific recognition of the AGR2.
Structural study have identified that the binding motif of aptamer is an intramolecular parallel G-quadruplex structure and
its structure and binding affinity are strongly dependent on the nature of the monovalent ion. Furthermore, with our design
of AGR2-aMB, AGR2 could be sensitively and selectively detected. This aptamer probe has great potential to serve as a
useful tool for early diagnosis and prognosis of cancer and for fundamental research to elucidate the biochemical functions
of AGR2.
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Introduction
Anterior gradient homolog 2 (AGR2) was identified initially as a
secretory factor expressed in the anterior region of the dorsal
ectoderm in Xenopuslaevis embryos, where it was postulated to
mediate the specification of dorsoanterior ectodermal fate,
particularly in the formation of the cement gland [1]. Clinical
studies have further shown that the AGR2 protein is overexpressed
in a wide range of human cancers, including carcinomas of the
esophagus, pancreas, breast, prostate, and lung [2–6]. More
biological studies in these cancer cell lines have indicated a
significant role for AGR2 in tumor-associated pathways, including
tumor growth, cellular transformation, cell migration, limb
regeneration, and metastasis [5,7–9]. However, the general
biochemical functions of AGR2 in human cells remain undefined,
and the signaling mechanisms that drive AGR2 to inhibit p53 are
still not clearly illustrated [10]. Therefore, the development of
molecular ligands specifically recognizing AGR2 is of great
significance to early diagnosis and prognosis of cancer and to
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fundamental research for the elucidation of the biochemical
functions of AGR2.
Various ligands have been developed for specific molecular
recognition, such as small molecules, antibodies, and peptides [11–
13]. More recently, another type of molecular ligand, named
aptamer, has drawn significant attention. Aptamers, single-
stranded modified or unmodified oligonucleotides (RNA or
DNA), are generated through in vitro selection process or SELEX
(Systematic Evolution of Ligands by EXponential enrichment)
with high binding affinity and specificity towards defined targets
[14,15]. The selected aptamers can recognize a wide variety of
targets, including small molecules, proteins, cells and tissues
relying on their diverse tertiary structures. Compared to antibod-
ies, aptamers have low molecular weight, fast tissue penetration
rate, high stability and low immunogenesis [16]. They can be
chemically synthesized with low cost and modified easily with
various reporters [17]. Furthermore, they can be ligated and/or
amplified by enzymes in vitro [18]. These advantages make
aptamers promising ligands for medical and pharmaceutical
research, such as drug development, disease diagnosis, and
targeted therapy [19].
The possibilities provided by aptamers are enormous, and some
aptamers have already shown many important applications in
bioanalysisand biomedicine [20–23]. Particularly, several apta-
mers have been generated against cancer-related proteins, such as
PDGF, VEGF, HER3, NFkB, tenascin-C, or PMSA [24–26].
Many aptameric sensors, probes and assays have been developed
to allow sensitive and selective detection of these cancer biomarker
proteins [27]. For instance, Yang et al has reported a light-
switching excimer aptamer probes for sensitive quantitative
detection of PDGF in cell media [28]. Kwon et al have developed
a functionalized polypyrrole nanotube with aptamer to build a
VEGF biosensor [29]. Aptamers have also been applied for
molecular imaging to in vivo characterize the complex pathogenic
activities that accompany tumor growth for disease early diagnosis
and pathogenesis measurement [30–33]. Since the targets for
aptamers could be intracellular, extracellular or cell-surface
biomolecules, various therapeutic methods have been developed
using the aptamers as targeting reagents [34–37], which greatly
broaden the range of targeted therapy. In addition, some
therapeutically useful aptamers have been found to inhibit
protein–protein interactions, such as receptor–ligand interactions,
and thereby function as antagonists [38].
In this study, using the bead-based and flow cytometry
monitored SELEX technology, we aimed to obtain specific
aptamers to AGR2 and study theirs structure and potential
function. Beads-based SELEX allowed the use of simple, yet
effective, flow cytometry analysis to monitor the progress of the
selection, avoiding the tedious, time consuming and radioactive
EMSA process [39–43]. After 14 rounds of selection, we have
identified a group of DNA aptamers that specifically bound to
AGR2 with high affinities. Structural studies on one of the
aptamer sequences, C14B, revealed an intramolecular parallel G-
quadruplex, and its structure and binding affinity to AGR2
depend on K+ ion intensively. Furthermore, we designed an
allosteric molecule beacon AGR2-aMB based on the identified
aptamer, which enables simple, sensitive and selective detection
AGR2. The aptamer sequences and AGR2-aMB reported in this
study are potentially useful tools for early diagnosis and prognosis
of cancer and for fundamental research to elucidate the
biochemical functions of AGR2.
Results and Discussion
Selection of DNA aptamers to recognize AGR2
To identify aptamers against AGR2, recombinant AGR2 was
fused with glutathione-S-transferase (GST) to facilitate the
attachment of the protein to solid supports (Sepharose GSH-
beads). The resulting AGR2-GST-beads were used as the positive
target in SELEX while the GST-beads as negative control to
remove non-specific surface binding sequences. The process of in
vitro sepharose-bead-based SELEX is schematically illustrated in
Figure 1.
An 87-nucleotide (87-nt) single-stranded DNA (ssDNA) library
with 45 random bases flanked by two primer sequences (22-nt and
20-nt) was subjected to the SELEX procedure. The library was
first allowed to interact with excess negative control beads, and
only the DNA sequences that did not bound to the GST-beads
were collected. The collected sequences were then incubated with
AGR2-GST-beads. After rigorous washing, those sequences that
either did not bind, or only weakly bound to the target were
discarded. Only the sequences that bound strongly enough were
retained on beads, and the bead-ssDNA complexes were collected
and amplified by PCR for the next round of selection. After
multiple rounds of selection, the subtraction process efficiently
reduced the DNA sequences that bound to the GST beads, while
those AGR2-specific aptamer candidates were gradually enriched.
The progress of the selection process was monitored by flow
cytometry. The stronger binding of DNA library to AGR2, the
more FAM labeled sequences bound to the beads, thus the higher
fluorescence intensity the beads would emit. With the increasing
number of selection cycles, steady increases in fluorescence
intensity on the target beads were observed (Figure 2a). The
binding affinity of the enriched library after 14 rounds of selection
was determined to be in the nanomolar range
(Kd = 64.165.4 nM), while there was no observable binding of
the library to control beads (Figure 2b). These results suggested
that the DNA aptamers specifically recognizing AGR2 were
enriched during the selection process.
Characterization of selected aptamer sequences
After 14 rounds of selection, the enriched DNA pool was cloned
and sequenced. The sequencing data for clones were analyzed by
using sequencing analysis software Clustal W 6.0 [44]. The
sequences were grouped based on the homology similarity of the
DNA sequences from individual clone. Among the sequences from
62 clones, there were two subfamilies each containing multiple
sequences with common features. One subfamily is guanosine-rich
sequences (22 clones), and the other is thymine-rich sequences (40
clones) (Figure S1). Four sequences were chosen and synthesized
for further characterization (Table S1): three sequences from G-
rich subfamily, C14A (appeared 2 times), C14B (appeared 3 times)
and C14C (appeared 5 times), and one sequence C14D (appeared
2 times) from T-rich subfamily. Only one T-rich sequence was
chosen because of T-rich sequences tend to from non-rigid tertiary
structures and the chance of being aptamer was thought to be very
low. As shown in Figure 2c, C14B can bind AGR2 with the
highest affinity (Kd = 13.167.2 nM). Titration of C14B to GST-
beads revealed no observable binding, establishing that the
binding target of C14B was indeed AGR2. Other three sequences
have similar binding constants to AGR2 but a little weaker than
C14B, in which the Kd of C14A is 20.965.2 nM, C14C is
44.667.0 nM and C14D is 48.4615.6 nM. (Figure S2).
Aptamer against Cancer Biomarker Protein
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Sequence optimization of aptamer C14B
Since C14B is the best aptamer we obtained from the four
sequences tested, it was choses for future optimization and
characterization. The length of C14B is 87mer, which is
disadvantageous for future applications because it is inconvenient
and expensive to synthesize such a long sequence. To identify the
binding region of the aptamer, the marginal sequences of
C14Bwas gradually truncated. Two truncated sequencesC14B0
and C14B1 from C14B were shown in Table 1. Subsequent
binding affinity experiments revealed that both C14B0
(8.563.6 nM) and C14B1 (19.165.1 nM) have similar Kd to
AGR2 as that of original C14B (13.167.2 nM). The majority of
eliminated sequences were primer sequences, implying that the
binding region of the aptamer was the middle of random
sequences and the primer sequences do not or contribute little
to the binding affinity of aptamer. C14B1 has five portions of poly-
G and we designed five truncated sequences by removing one of
poly-G portion each (Table S2). Removal of any poly-G portion
would destroy its binding affinity to certain extend (Figure S3),
suggesting the whole G-motif is required for aptamer binding.
Taking together, these results indicate that C14B1, which was only
33 mer, was the essential binding region to AGR2. Thus, C14B1
was applied for further characterization and probe design.
Selectivity of Aptamer C14B1
In order to demonstrate the specific interaction between AGR2
and C14B1, three control proteins BSA, thrombin and trypsin
were coupled with the NHS-sepharose-beads and then were
incubated with C14B1. As shown in Figure 3, C14B1 could bind
to target AGR2 strongly, while there were no or little binding
affinity towards thrombin, BSA and trypsin, demonstrating the
high selectivity of the aptamer.
Aptamer C14B1 is an Intramolecular Parallel G-
quadruplex
Further examination revealed that C14B1 has multiple stretches
of guanines (CGGGTGGGAGTTGTGGGGGGGGGTGG-
GAGGGT). It is well-known that guanine-rich sequences can
fold into four-stranded secondary structures called quadruplexes.
According to G-Quadruplex prediction formula d(G3+N1-7G3+N1-
7G3+N1-7G3+) [45], C14B1 had great probability to form a G-
Quadruplex structure. In the G-quadruplex, the planar square
arrangement of four guanines (tetrad) is stabilized by Hoogsteen
hydrogen bonding. Depending on the direction of the strands or
parts of a strand that form the tetrads, structures may be described
as parallel or antiparallel. Moreover, these quadruplexes can form
through the intermolecular association of four or two DNA
molecules, or by the intramolecular folding of a single strand
containing four blocks of guanines [46] CD experiments were
performed to investigate the secondary structure of apta-
merC14B1. The CD spectrum of C14B1 showed a negative peak
near 240 nm and a positive peak near 260 nm, a typical spectrum
of a parallel G-quadruplex [47]. In order to investigate whether
C14B1 forms an intermolecular 4 stranded or intramolecular
Figure 1. Schematics of systematic evolution of DNA aptamers against AGR2. In sepharose-beads-based SELEX process for protein AGR2,
the GST-beads were incubated with the ssDNA library for counter-selection to remove nonspecific sequences. The unbound DNAs were then
incubated with AGR2-GST-beads for target-selection. After harshly washing, the AGR2-specific DNA sequences were subsequently amplified by PCR
for the next round of selection, or for cloning and sequencing to identify individual aptamers after flow cytometry analysis.
doi:10.1371/journal.pone.0046393.g001
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single stranded G-quadruplex structure, the dependence of
melting temperature on the concentration of C14B1 was studied
[48]. The melting temperature of C14B1 was found to be 59uC,
which was independent of oligonucleotide concentration (Figure
S4), indicating that the aptamer forms an intramolecular G-
quadruplex.
Binding Affinity and Structure Stability of C14B1 is K+
Dependent
Many DNA aptamers have been found to form G-quadruplex
structures [49–51]. It is well established that the existence of a
monovalent cation (especially potassium) in the center of these
tetrads can significantly stabilize G-quadruplexes [52–54]. Thus,
we investigated how a cation would affect the structural stability of
C14B1 and its binding activity towards to AGR2. As shown in
Figure 4a, the stability of the C14B1 G-quadruplex structure is
strongly dependent on the presence of the monovalent ion. With
60 mM of KCl, strong CD peaks were observed, suggesting the
formation of stable G-quadruplex structure. Replacing KCl with
the same concentration of LiCl, NaCl, and MgCl2 led to a
dramatic intensity decrease in CD.
We further studied the effect of K+ concentration on the
stability of G-quadruplex. In Figure 4b, addition of 0.1 mM K+ in
phosphate buffer dramatically increased the CD intensity at 240
and 260 nm. CD absorption intensity enhanced with the increase
of K+ concentration and reached a plateau when K+ concentration
was higher than 20 mM. The binding affinity of C14B1 at
different concentrations of K+ was also investigated. As the flow
cytometry results shown in Figure 4c, very weak binding of C14B1
towards AGR2-beads was observed when there was no K+ in the
buffer, and the binding affinity kept increasing with the addition of
K+. The binding constants of C14B1 were measured and
compared in the presence or absence of K+ (Figure 4d). The Kd
value in the presence of K+ was determined to be 6.261.9 nM.
Figure 2. Enrichment of DNA sequences that bind to AGR2-GST-beads. a) Flow cytometry assay to monitor the binding of a selected pool
with AGR2 (target protein) and GST (control protein). The red curve represents the background binding of unselected library. For the target protein
AGR2, there was an increase in binding capacity of the pool as the selection progressed, while there was no observable change for the control protein
GST. The final concentration of the selected pool in binding buffer was 100 nM. b) Determination of the dissociation constant of the enriched library
and unselected library to AGR2. c) Fluorescence measurements to determine the dissociation constant of selected aptamer C14B. Two negative
controls, GST-beads and GSH-beads, were carried out. The data were the average of triplicate experiment results.
doi:10.1371/journal.pone.0046393.g002
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The results demonstrated that formation of G-quadruplex is
important for the binding capability of aptamer C14B1 to its
target, which is highly K+ dependent.
Allosteric molecular beacons for detection AGR2
Clinical studies have already shown that the AGR2 protein is
overexpressed in a wide range of human cancers. The sensitive
and selective detection of AGR2 is thus of great importance to
early cancer diagnostics. Herein, by applying the selected and
optimized aptamer C14B1, we designed and developed an
allosteric molecular beacon against AGR2, named AGR2-aMB,
which converts the molecule recognition property of aptamer to
fluorescence flow cytometry signal for AGR2 sensing [55]. Figure 5
illustrates the working principle of AGR2-aMB. An AGR2-aMB is
a ssDNA consisting of an streptavidin (SA) aptamer sequence [56],
a C14B1 sequence, a short sequence complimentary to a small
part of the SA aptamer sequence, and a fluorophore. A stable
hairpin structure is formed by intramolecular hybridization
between the SA aptamer sequence and the complementary
sequence, temporarily disabling the probe’s ability to bind with
SA beads. Consequently, when incubated with SA beads, no probe
can bind to SA beads, and the beads display very low fluorescence.
In the presence of AGR2, however, the C14B1 sequence in the
loop of aMB binds to the target sequence, which in turn disrupts
the hairpin structure to free the SA binding sequence, thereby
activating the probe’s binding affinity to SA beads. Thus, the
AGR2-bound probe will bind to SA beads, which will fluoresce
strongly because the probe is FAM labeled. Target molecules can
be detected and quantified by reading the fluorescence intensity of
SA beads through flow cytometer.
We designed AGR2-aMB, with the following sequence:
CGACGCACCGATCGCAGGTTCGGGATTTTCGGGTGG-
GAGTTGTGGGGGGGGGTGGGAGGGTT-FAM, where the
AGR2 binding region is underlined and the SA aptamer sequence
is in bold. Stable hairpin structure is formed by intramolecular
hybridization (Figure S5). In our experiment, when only AGR2-
aMB incubated with SA beads, no probe can bind to SA beads,
and the beads fluoresced very weakly. In the presence of AGR2,
however, the fluorescence intensity of SA beads increase
significantly, suggesting the binding of AGR2-bound probe to
SA beads. With the increase of AGR2 concentration, steady
increases in fluorescence intensity on the target beads were
observed. AGR2 at 100 nM concentration can be easily detected
(Figure 6a). A series of proteins including BSA, trypsin, thrombin,
and IgG were employed as controls (500 nM), and no distinct
fluorescent signals were observed (Figure 6b), indicating an
excellent specificity of the AGR2-aMB towards target molecule.
The results demonstrated the sensitivity and specificity of the
allosteric molecular beacon probe, implying its potential for
application in real sample analysis, such as protein function study
and disease diagnosis.
In conclusion, we have developed new aptamer probes for
specific recognition of the AGR2. In the SELEX process, AGR2-
GST fused protein was used as the target protein, and linked to
sepharose beads through the mild, yet specific, noncovalent GST-
Glutathione interaction. Beads-based SELEX allowed the use of
simple, yet effective, flow cytometry analysis to monitor the
progress of the selection, avoiding the tedious, time consuming and
radioactive EMSA process. Through multiple rounds of selection
with GST as a control, we have identified aptamers that selectively
recognize AGR2 with nanomolar Kd values. CD measurements
and melting-temperature assays demonstrated that the optimal
aptamer C14B1 forms an intramolecular parallel G-quadruplex
structure and its structure and binding affinity are strongly
dependent on the nature of the monovalent ion. Furthermore,
with our design of AGR2-aMB, AGR2 could be sensitively and
selectively detected The aptamer sequences and sensors reported
here has great potential to serve as a useful tool for early diagnosis
and prognosis of cancer and for fundamental research to elucidate
the biochemical functions of AGR2.
Materials and Methods
Initial library design
The HPLC-purified library containing a central randomized
sequence of 45 nucleotides flanked by two 20-nt and 22-nt primer
hybridization sites. Initial library was: 59-TCT CGG ACG CGT
GTG GTC GG-N45-C TCG CTG CCT GGC CCT AGA
GTG-39, forward primer: 59-FAM-TCT CGG ACG CGT GTG




Kd = 13.167.2 nM
C14B0 CGGGTGGGAGTTGTGGGGGGGGGTGGGAGGGTTCTTTGTTTGATCTTTCTCGCTGCCTGGCCCTAGAGTG Kd = 8.563.6 nM
C14B1 CGGGTGGGAGTTGTGGGGGGGGGTGGGAGGGTT Kd = 19.165.1 nM
doi:10.1371/journal.pone.0046393.t001
Figure 3. Specificity of aptamer C14B1 against AGR2 and three
control proteins, BSA, Trypsin and Thrombin. The signal-to-
background ratio (SBR) is defined as the fluorescence signal ratio of
FAM-labeled aptamer to FAM-labeled random sequence when treating
with protein modified beads. The data were the average of triplicate
experiment results.
doi:10.1371/journal.pone.0046393.g003
Aptamer against Cancer Biomarker Protein
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GTC GG-39, reverse primer: 59-Biotin-CAC TCT AGG GCC
AGG CAG CGA G-39.
Preparation of AGR2-GST fused protein
The plasmid pGEX-GST-AGR2 was transformed into the
engineering strain BL-21 and the GST-tagged AGR2 protein was
expressed. After purification with glutathione sepharose beads (GE
healthcare) by affinity chromatography, the GST-AGR2 fused
protein was linked to sepharose beads for positive selection. After
being washed several times with W1 buffer (25 mM Tris-HCl
pH 7.5, 150 mM NaCl, 0.07% b-mercaptoethanol, 1% Triton X-
100), the final purified AGR2-GST-beads were stored in sterilized
PBS buffer. Flow cytometry analysis with TAMRA-labeled anti-
AGR2 monoclonal antibody (Santa Cruz) and SDS-PAGE
indicated that the GST-AGR2 fused protein was successfully
linked to the sepharose beads.
Selection of AGR2 binding aptamers
The procedures of selection were as follows. The ssDNA pool
(200 pmol) dissolved in binding buffer (200 mL, 16PBS buffer
containing 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and
2.0 mM KH2PO4, pH 7.4) was denatured by heating at 95uC for
Figure 4. Characterization of the aptamer C14B1. a) CD spectra of the aptamer C14B1 in the presence of different cations. This aptamer has a
positive band near 260 nm that can be assigned to a parallel quadruplex structures. b)The structural stability of the aptamer relies heavily on [K+]. c)
Fluorescent signal migration of C14B1 binding to AGR2-beads at different concentration of K+ was investigated. d) The binding constants of C14B1 in
the buffer w/ and w/o K+. The data were the average of triplicate experiment results.
doi:10.1371/journal.pone.0046393.g004
Figure 5. Working principle of allosteric molecular beacon
probe for sensitive and selective detection of AGR2 based on
fluorescent flow cytometry analysis.
doi:10.1371/journal.pone.0046393.g005
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5 min, then quickly cooled on ice for 10 min, and subsequently
incubated for another 10 min at room temperature before
binding. The ssDNA pool was then incubated with negative
GST beads (1.06105 beads) for counter selection to remove
sequences non-specifically binding to GST beads. After filtering
with a homemade filter column, the filtrate was incubated with
positive AGR2-GST-beads (1.06105 beads) at 37uC for 45 min.
The unbound or nonspecifically bound oligoes were removed by
filtration. The sequences bound to the target-coated beads were
then amplified by PCR with FAM and biotin-labeled primers (5–
15 cycles of 0.5 min at 94uC, 0.5 min at 53uC, and 0.5 min at
72uC, followed by 5 min at 72uC; the Easytaq plus polymerase
and dNTPs were obtained from Transgen Beijing). After
denaturation in NaOH (0.1 M), the selected sense ssDNA was
separated from the biotinylated antisense ssDNA strand on
streptavidin-coated sepharose beads (GE healthcare) and used
for next round selection. For the first-round selection, the amount
of initial ssDNA pool was 5 nmol, dissolved in 500 mL binding
buffer, and the counter-selection step was eliminated. To acquire
aptamers with high affinity and specificity, the selection strength
was enhanced gradually by increasing the number of washes (from
three to ten times with 200 mL 16PBS buffer each) and decreasing
the amount of the ssDNA library per round (from 200 to
150 pmol).
Cloning and DNA sequencing
The resulting pool from the 14th round was PCR amplified,
cloned and sequenced (Shanghai Sangon sequencing facility). The
resulting 62 sequences were subjected to multiple sequence
alignment analysis by using Clustal W 6.0 software to discover
highly conserved motifs in groups of selected DNA sequences. The
discovered consensus sequences with high repeats among selected
pools were then chemically synthesized for further testing.
Flow cytometric analysis
To monitor the enrichment of aptamers after selection, the
FAM-labeled ssDNA pool was incubated with 56104 AGR2-
GST-beads or GST-beads in binding buffer (200 mL) at 37uC for
45 min. Beads were washed three times with 200 mL binding
buffer by means of filtration, and suspended in binding buffer
(250 mL). The fluorescence intensity of the resulting beads was
monitored with a FACSAria cytometer (Becton Dickinson
Immuno cytometry systems) by counting 10000 events. The
binding affinities of aptamers were determined by incubating
AGR2-GST-beads (56104) with various concentrations of FAM-
labeled aptamers (pre-heat-treated) in binding buffer (200 mL) at
37uC for 45 min in the dark. Beads were then washed three times
with the binding buffer, then resuspended in binding buffer
(250 mL) and subjected to flow cytometry analysis. The FAM-
labeled unselected ssDNA library was used as negative control for
the nonspecific binding evaluation. All binding experiments were
repeated two to four times. The mean fluorescence intensity of
target protein labeled by aptamers was used to evaluate binding
affinity by subtracting the mean fluorescence intensity of
nonspecific binding produced by unselected ssDNA library. The
dissociation constants (Kd) of the fluorescent ligands were obtained
by fitting the dependence of fluorescence intensity of specific
binding on the concentration of the ligands to the equation (1):
Y = BmaxX/(Kd+X) using SigmaPlot software.
Circular dichroism spectroscopy
CD measurements were carried out on a Jasco J-810 spectropo-
larimeter equipped with a programmable temperature-control unit
(Julabo HP-4). The concentration of DNA samples were 2 mM.
Before the CD spectrum measurement, the DNA samples were
annealed by heating to 95uC for 5 min, then rapidly cooled on ice
for 10 min, and incubated for another 10 min at room temperature.
The spectra from 400 to 200 nm were obtained by using 1 nm slit
width and 0.1 nm scanning resolution. Each CD spectrum was an
average of 8 scans with the buffer background subtracted.
UV thermal-denaturation experiment
UV absorbance and melting studies were carried out on an
Agilent 8453 spectrophotometer equipped with a programmable
temperature-control unit (Agilent 89090A). Melting temperatures
(Tm) were taken as the temperature of half-dissociation of the
Figure 6. Evaluation of the performance of AGR2-aMB. a) Response of AGR2-aMB to different concentrations of AGR2 in Tris-HCl buffer. b)
Response of AGR2-aMB to different targets including AGR2 (100 nM), BSA, IgG, Trypsin and Thrombin (500 nM each for control proteins). The data
were the average of triplicate experiment results.
doi:10.1371/journal.pone.0046393.g006
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quadruplex and were obtained from the maximum of the first
derivative dA/dT plots at 295 nm. The heat-treated DNA
solutions at several concentrations were introduced into a quartz
cuvette and overlaid with a thin layer of silicone oil to prevent
evaporation. The optical path length was 1 cm. Absorbance and
temperature were recorded every 2uC.
Evaluation of AGR2-aMB
AGR2-aMB (40 nM) was annealed by heating to 95uC for
5 minutes in 200 mL Tris-HCl buffer (25 mM Tris-HCl, 120 mM
NaCl, 0.5 mM KCl, 2 mM MgCl2 at pH 7.4), and then rapidly
cooled on ice for 10 min, and subsequently waiting for another
10 min at room temperature before use. To the solution of AGR2-
aMB, various concentrations of AGR2 were added and the resulting
solutions were allowed to incubate at 37uC for 30 min. To the
mixture, 1 mL of streptavidin beads (about 56104 beads) were
added and the mixture was allowed to set for 45 min in dark. After
washing twice with Tris-HCl buffer, SA beads were filtered to
eliminate unbound AGR2-aMB and resuspended in Tris-HCl
buffer solution 250 mL before flow cytometry analysis. In selectivity
tests, BSA (Tagene Biotechnology Xiamen), trypsin (Dingguo
Beijing), thrombin (alfa) and IgG (Dingguo Beijing) were used.
Supporting Information
Figure S1 The sequences of 62 clones. One subfamily is
guanosine-rich sequences (22 clones), and the other is thymine-rich
sequences (40 clones).
(TIF)
Figure S2 The dissociation constant measurement of
C14A, C14B, C14C and C14D against AGR2 GST and GSH.
(TIF)
Figure S3 Flow cytometry assay to monitor the binding
of C14B1 and its five truncated sequences with a) AGR2
(target protein) and b) GST (control protein).
(TIF)
Figure S4 UV thermal-denaturation experiment of
C14B1. Denaturation profiles obtained at 295 nm for the
aptamer at three different concentrations (2 mM, 4 mM, 8 mM).
The Tm (59uC) at 295 nm is independent of oligonucleotide
concentration, indicating that the aptamer forms an intramolec-
ular G-quartet.
(TIF)
Figure S5 The secondary structure of AGR-aMB. Stable
hairpin structure is formed by intramolecular hybridization
between the SA aptamer sequence and the complementary
sequence of C14B1.
(TIF)
Table S1 The sequences of C14A, C14B, C14C and
C14D, and their Kd to AGR2.
(DOC)
Table S2 The truncated sequences by removing one of
poly-G portion each from C14B1.
(DOCX)
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